This proposal evaluates the translational potential of optogenetic therapy, an approach whereby visual function is achieved through the use of a molecular prosthesis that transmits its signals to downstream visual circuits. Studies in vitro and in vivo in animal models by our collaborators (and others) have demonstrated that light-activated chloride pumps or channels can be introduced into specific retinal cell types in diseased or atrophic retinas. There, these molecular prostheses can permit visual responses where before, there were none. The present program aims to address the knowledge gaps and technical limitations relevant to development of optogenetic therapy in two different paradigms: 1) Physiologically optimized forms of Halorhodopsin (NpHR) will be used to activate function of failing cone photoreceptors after the rod photoreceptors have degenerated;2) Optimized Channelrhodopsins (ChRd) will be used to confer light responsiveness to second order retinal neurons in degenerated retinas. We will design and develop the appropriate vectors, delivery strategies and outcome measures for each paradigm, will carry out the prerequisite preclinical safety and efficacy studies, and will bring one of the studies (NpHR) to clinical trial. In the process, novel strategies of altering the transduction characteristics of adeno-associated virus (AAV) will be developed, new surgical approaches which could be applied to human eyes will be devised, and sensitive, noninvasive, clinically relevant outcome measures will be defined. Simultaneous with development of the technology, we will evaluate the bioethics of gene therapy-mediated delivery of molecular prostheses in humans. This comprehensive program benefits greatly from the wisdom and experience of many talented collaborators and advisors and takes advantage of the infrastructure that the PI has already developed for ocular gene therapy translational research. Successful application of optogenetic therapy will expa

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-NDPA-A (01))
Program Officer
Wehrle, Janna P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Landegger, Lukas D; Pan, Bifeng; Askew, Charles et al. (2017) A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol 35:280-284
Castle, Michael J; Turunen, Heikki T; Vandenberghe, Luk H et al. (2016) Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Methods Mol Biol 1382:133-49
Garanto, Alejandro; Chung, Daniel C; Duijkers, Lonneke et al. (2016) In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet 25:2552-2563
Carvalho, Livia S; Vandenberghe, Luk H (2015) Promising and delivering gene therapies for vision loss. Vision Res 111:124-33
Drivas, Theodore G; Wojno, Adam P; Tucker, Budd A et al. (2015) Basal exon skipping and genetic pleiotropy: A predictive model of disease pathogenesis. Sci Transl Med 7:291ra97
Cheever, Thomas R; Berkley, Dale; Braun, Serge et al. (2015) Perspectives on best practices for gene therapy programs. Hum Gene Ther 26:127-33
Zinn, Eric; Pacouret, Simon; Khaychuk, Vadim et al. (2015) In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. Cell Rep 12:1056-68
Vandenberghe, Luk H (2015) What Is Next for Retinal Gene Therapy? Cold Spring Harb Perspect Med 5:
Cronin, Therese; Vandenberghe, Luk H; Hantz, P├ęter et al. (2014) Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 6:1175-90
Zinn, Eric; Vandenberghe, Luk H (2014) Adeno-associated virus: fit to serve. Curr Opin Virol 8:90-7

Showing the most recent 10 out of 13 publications